HLS Therapeutics Inc. (HLS.TO)
CAD 3.62
(0.56%)
CAD 3.62
(0.56%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 63.07 Million USD | 2.61% |
| 2022 | 61.46 Million USD | 2.43% |
| 2021 | 60 Million USD | 6.95% |
| 2020 | 56.1 Million USD | 3.6% |
| 2019 | 54.16 Million USD | -11.81% |
| 2018 | 61.41 Million USD | -18.2% |
| 2017 | 75.08 Million USD | 38.96% |
| 2016 | 54.03 Million USD | 170.75% |
| 2015 | 19.95 Million USD | -72.99% |
| 2014 | 73.87 Million USD | -7.03% |
| 2013 | 79.46 Million USD | -31.82% |
| 2012 | 116.55 Million USD | 48.01% |
| 2011 | 78.74 Million USD | -10.62% |
| 2010 | 88.09 Million USD | 22.57% |
| 2009 | 71.87 Million USD | 5.47% |
| 2008 | 68.14 Million USD | -32.25% |
| 2007 | 100.58 Million USD | 102.55% |
| 2006 | 49.66 Million USD | -27.19% |
| 2005 | 68.2 Million USD | -12.35% |
| 2004 | 77.8 Million USD | -6.5% |
| 2003 | 83.21 Million USD | 134.27% |
| 2002 | 35.51 Million USD | 6.83% |
| 2001 | 33.25 Million USD | -66.69% |
| 2000 | 99.83 Million USD | 4.4% |
| 1999 | 95.62 Million USD | -5.62% |
| 1998 | 101.31 Million USD | 32.89% |
| 1997 | 76.24 Million USD | 27.81% |
| 1996 | 59.65 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 14.51 Million USD | 16.4% |
| 2024 Q1 | 12.47 Million USD | -21.37% |
| 2023 FY | 63.07 Million USD | 2.61% |
| 2023 Q1 | 14.75 Million USD | -5.86% |
| 2023 Q2 | 16.41 Million USD | 11.25% |
| 2023 Q3 | 16.03 Million USD | -2.31% |
| 2023 Q4 | 15.86 Million USD | -1.08% |
| 2022 Q1 | 14.55 Million USD | -7.23% |
| 2022 FY | 61.46 Million USD | 2.43% |
| 2022 Q3 | 15.7 Million USD | 1.11% |
| 2022 Q2 | 15.53 Million USD | 6.71% |
| 2022 Q4 | 15.67 Million USD | -0.18% |
| 2021 Q3 | 15.06 Million USD | 0.77% |
| 2021 Q1 | 14.31 Million USD | -13.17% |
| 2021 FY | 60 Million USD | 6.95% |
| 2021 Q2 | 14.94 Million USD | 4.41% |
| 2021 Q4 | 15.69 Million USD | 4.18% |
| 2020 Q3 | 13.12 Million USD | 4.16% |
| 2020 Q4 | 16.48 Million USD | 25.56% |
| 2020 Q2 | 12.6 Million USD | -9.25% |
| 2020 FY | 56.1 Million USD | 3.6% |
| 2020 Q1 | 13.89 Million USD | -0.34% |
| 2019 Q1 | 13.17 Million USD | -20.94% |
| 2019 Q2 | 13.62 Million USD | 3.44% |
| 2019 FY | 54.16 Million USD | -11.81% |
| 2019 Q4 | 13.93 Million USD | 3.81% |
| 2019 Q3 | 13.42 Million USD | -1.46% |
| 2018 Q2 | 16.3 Million USD | 23.84% |
| 2018 FY | 61.41 Million USD | -18.2% |
| 2018 Q4 | 16.66 Million USD | 9.02% |
| 2018 Q3 | 15.28 Million USD | -6.27% |
| 2018 Q1 | 13.16 Million USD | -82.46% |
| 2017 Q1 | 15.55 Million USD | -1.54% |
| 2017 FY | 75.08 Million USD | 38.96% |
| 2017 Q4 | 75.08 Million USD | 269.99% |
| 2017 Q3 | 20.29 Million USD | 7.59% |
| 2017 Q2 | 18.86 Million USD | 21.27% |
| 2016 Q3 | - USD | 0.0% |
| 2016 FY | 54.03 Million USD | 170.75% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q4 | 15.79 Million USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 FY | 19.95 Million USD | -72.99% |
| 2015 Q1 | - USD | -100.0% |
| 2014 FY | 73.87 Million USD | -7.03% |
| 2014 Q4 | 20.46 Million USD | 7.28% |
| 2014 Q1 | 17.68 Million USD | 1.27% |
| 2014 Q2 | 17.59 Million USD | -0.51% |
| 2014 Q3 | 19.07 Million USD | 8.43% |
| 2013 Q3 | 19.59 Million USD | -6.03% |
| 2013 Q1 | 21.43 Million USD | -18.37% |
| 2013 FY | 79.46 Million USD | -31.82% |
| 2013 Q4 | 17.46 Million USD | -10.87% |
| 2013 Q2 | 20.85 Million USD | -2.71% |
| 2012 Q4 | 26.25 Million USD | -26.92% |
| 2012 FY | 116.55 Million USD | 48.01% |
| 2012 Q3 | 35.92 Million USD | 23.02% |
| 2012 Q2 | 29.2 Million USD | 22.32% |
| 2012 Q1 | 23.87 Million USD | 5.64% |
| 2011 Q1 | 21.36 Million USD | 2.52% |
| 2011 Q2 | 19.13 Million USD | -10.4% |
| 2011 Q3 | 18.27 Million USD | -4.49% |
| 2011 Q4 | 22.59 Million USD | 23.62% |
| 2011 FY | 78.74 Million USD | -10.62% |
| 2010 Q2 | 24.22 Million USD | -0.41% |
| 2010 FY | 88.09 Million USD | 22.57% |
| 2010 Q1 | 24.32 Million USD | 6.71% |
| 2010 Q4 | 20.83 Million USD | 12.78% |
| 2010 Q3 | 18.47 Million USD | -23.75% |
| 2009 Q3 | 14.13 Million USD | -31.9% |
| 2009 Q2 | 20.76 Million USD | 97.97% |
| 2009 FY | 71.87 Million USD | 5.47% |
| 2009 Q4 | 22.79 Million USD | 61.27% |
| 2009 Q1 | 10.48 Million USD | 97.31% |
| 2008 FY | 68.14 Million USD | -32.25% |
| 2008 Q4 | 5.31 Million USD | -72.81% |
| 2008 Q3 | 19.54 Million USD | -20.47% |
| 2008 Q2 | 24.57 Million USD | 21.56% |
| 2008 Q1 | 20.21 Million USD | -13.3% |
| 2007 Q1 | 24.02 Million USD | 162.48% |
| 2007 FY | 100.58 Million USD | 102.55% |
| 2007 Q4 | 23.32 Million USD | 5.52% |
| 2007 Q3 | 22.1 Million USD | -13.03% |
| 2007 Q2 | 25.41 Million USD | 5.75% |
| 2006 Q1 | 15.34 Million USD | -9.64% |
| 2006 Q2 | 15.37 Million USD | 0.2% |
| 2006 Q3 | 9.14 Million USD | -40.56% |
| 2006 Q4 | 9.15 Million USD | 0.16% |
| 2006 FY | 49.66 Million USD | -27.19% |
| 2005 Q2 | 15.97 Million USD | 0.07% |
| 2005 Q3 | 17.78 Million USD | 11.38% |
| 2005 Q4 | 16.98 Million USD | -4.52% |
| 2005 Q1 | 15.95 Million USD | -13.3% |
| 2005 FY | 68.2 Million USD | -12.35% |
| 2004 Q3 | 15.44 Million USD | -23.14% |
| 2004 Q4 | 18.4 Million USD | 19.19% |
| 2004 FY | 77.8 Million USD | -6.5% |
| 2004 Q1 | 21.84 Million USD | -9.26% |
| 2004 Q2 | 20.09 Million USD | -8.03% |
| 2003 Q1 | 16.85 Million USD | 79.03% |
| 2003 FY | 83.21 Million USD | 134.27% |
| 2003 Q4 | 24.07 Million USD | 28.38% |
| 2003 Q3 | 18.75 Million USD | -15.42% |
| 2003 Q2 | 22.17 Million USD | 31.59% |
| 2002 FY | 35.51 Million USD | 6.83% |
| 2002 Q4 | 9.41 Million USD | 10.05% |
| 2002 Q3 | 8.55 Million USD | -8.89% |
| 2002 Q2 | 9.38 Million USD | 9.9% |
| 2002 Q1 | 8.54 Million USD | -0.39% |
| 2001 Q1 | 8.39 Million USD | -69.24% |
| 2001 FY | 33.25 Million USD | -66.69% |
| 2001 Q4 | 8.57 Million USD | 8.53% |
| 2001 Q3 | 7.9 Million USD | -9.54% |
| 2001 Q2 | 8.73 Million USD | 4.05% |
| 2000 Q2 | 24.37 Million USD | 4.13% |
| 2000 Q1 | 23.4 Million USD | -21.4% |
| 2000 FY | 99.83 Million USD | 4.4% |
| 2000 Q4 | 27.29 Million USD | 5.44% |
| 2000 Q3 | 25.88 Million USD | 6.2% |
| 1999 Q4 | 29.77 Million USD | 23.54% |
| 1999 Q2 | 23.47 Million USD | 32.65% |
| 1999 Q1 | 17.69 Million USD | -10.75% |
| 1999 FY | 95.62 Million USD | -5.62% |
| 1999 Q3 | 24.1 Million USD | 2.7% |
| 1998 FY | 101.31 Million USD | 32.89% |
| 1998 Q4 | 19.82 Million USD | 35.11% |
| 1998 Q2 | 31.44 Million USD | -20.0% |
| 1998 Q1 | 39.3 Million USD | 0.0% |
| 1998 Q3 | 14.67 Million USD | -53.34% |
| 1997 Q3 | 14.54 Million USD | -25.2% |
| 1997 FY | 76.24 Million USD | 27.81% |
| 1997 Q2 | 19.44 Million USD | 23.6% |
| 1997 Q1 | 15.73 Million USD | 0.0% |
| 1996 FY | 59.65 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Aurora Cannabis Inc. | 270.28 Million CAD | 76.664% |
| Avicanna Inc. | 16.79 Million CAD | -275.631% |
| Avant Brands Inc. | 26.34 Million CAD | -139.425% |
| Cardiol Therapeutics Inc. | - CAD | -Infinity% |
| Crescita Therapeutics Inc. | 17.52 Million CAD | -259.97% |
| Knight Therapeutics Inc. | 328.19 Million CAD | 80.782% |
| MediPharm Labs Corp. | 33.06 Million CAD | -90.775% |
| OrganiGram Holdings Inc. | 149.2 Million CAD | 57.727% |
| Canopy Growth Corporation | 297.14 Million CAD | 78.773% |
| Willow Biosciences Inc. | 1.17 Million CAD | -5281.741% |
| Auxly Cannabis Group Inc. | 101.07 Million CAD | 37.599% |